CA2166312A1 - Compositions for nasal administration of desmopressin - Google Patents

Compositions for nasal administration of desmopressin

Info

Publication number
CA2166312A1
CA2166312A1 CA002166312A CA2166312A CA2166312A1 CA 2166312 A1 CA2166312 A1 CA 2166312A1 CA 002166312 A CA002166312 A CA 002166312A CA 2166312 A CA2166312 A CA 2166312A CA 2166312 A1 CA2166312 A1 CA 2166312A1
Authority
CA
Canada
Prior art keywords
composition
desmopressin
nasal administration
container
vasopressin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002166312A
Other languages
French (fr)
Other versions
CA2166312C (en
Inventor
Alan Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Alan Harris
Ferring A.B.
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alan Harris, Ferring A.B., Ferring B.V. filed Critical Alan Harris
Publication of CA2166312A1 publication Critical patent/CA2166312A1/en
Application granted granted Critical
Publication of CA2166312C publication Critical patent/CA2166312C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

An aqueous composition for spray nasal administration of a synthetic analog of vasopressin (desmopressin; 1-deamino-8-D-arginine-vasopressin) contains between 2.5 and 75 µg per 100 µl. The composition may additionally contain an osmotic-pressure controlling agent, such as sodium chloride, a preservative, such as chlorobutanol or benzalkonium chloride, and a buffer stabilizing the pH between about 4 and 6. Buffers containing citrate and/or phosphate are preferred. Also disclosed is a sealed container filled with the composition, an assembly comprising the container and a spray pump, and the use of the composition, the container, and the assembly in the management of urinary disorders.
CA002166312A 1993-06-29 1994-06-22 Compositions for nasal administration of desmopressin Expired - Fee Related CA2166312C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8489493A 1993-06-29 1993-06-29
US084,894 1993-06-29
PCT/SE1994/000623 WO1995001183A1 (en) 1993-06-29 1994-06-22 Compositions for nasal administration of desmopressin

Publications (2)

Publication Number Publication Date
CA2166312A1 true CA2166312A1 (en) 1995-01-12
CA2166312C CA2166312C (en) 2002-04-23

Family

ID=22187889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002166312A Expired - Fee Related CA2166312C (en) 1993-06-29 1994-06-22 Compositions for nasal administration of desmopressin

Country Status (20)

Country Link
US (1) US5498598A (en)
EP (1) EP0708657B1 (en)
JP (1) JPH09502425A (en)
KR (1) KR100193104B1 (en)
CN (1) CN1101701C (en)
AT (1) ATE203412T1 (en)
CA (1) CA2166312C (en)
CZ (1) CZ282456B6 (en)
DE (1) DE69427820T2 (en)
DK (1) DK0708657T3 (en)
ES (1) ES2158898T3 (en)
GR (1) GR3036936T3 (en)
HK (1) HK1000906A1 (en)
HU (1) HU221617B1 (en)
NZ (1) NZ268442A (en)
PL (1) PL176317B1 (en)
PT (1) PT708657E (en)
RU (1) RU2135204C1 (en)
SK (1) SK282844B6 (en)
WO (1) WO1995001183A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE193892T1 (en) * 1993-06-29 2000-06-15 Ferring Bv SYNTHESIS OF CYCLIC PEPTIDES
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5674850A (en) * 1993-12-23 1997-10-07 Ferring Ab High purity desmopressin produced in large single batches
SE9400918L (en) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabilized composition for oral administration of peptides
US5763398A (en) * 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
GB9614235D0 (en) * 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces
US5922680A (en) * 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
JP2001233787A (en) 2000-02-04 2001-08-28 Patents Exploitation Co Bv Small-and medium-sized peptide-containing pharmacological composition
US6641799B2 (en) 2002-04-03 2003-11-04 Nos Spray, Inc. Nasal spray for decongesting nasal passages
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2003269747A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited A stable aqueous composition of a peptide
PT1530967E (en) * 2003-11-13 2006-09-29 Ferring Bv PACKAGING BLISTER AND A SOLID DOSAGE FORM WHICH UNDERSTANDS DESMOPRESSIN.
SE0600482L (en) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Pharmaceutical composition comprising desmopressin, silica and starch
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
CN101372504B (en) * 2007-08-22 2011-05-18 深圳翰宇药业股份有限公司 Method for purifying desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
PT2712622T (en) 2008-05-21 2016-10-13 Ferring Bv Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
KR101755042B1 (en) * 2008-12-22 2017-07-06 알레간 인코포레이티드 A device for intranasal desmopressin administration
AU2015261630B2 (en) * 2008-12-22 2017-09-14 Acerus Pharmaceuticals USA, LLC Intranasal desmopressin administration
US20100160214A1 (en) * 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
PT4104848T (en) * 2009-06-18 2024-01-04 Acerus Pharmaceuticals Usa Llc Safe desmopressin administration
CN102440957B (en) * 2011-12-16 2013-09-25 深圳市健元医药科技有限公司 Terlipressin acetate nasal cavity spray and preparation method thereof
CN107206000A (en) 2014-12-22 2017-09-26 阿鲁兹特拉生物有限公司 Prevent and treat the metastatic disease in the cancer patient of thrombocythemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) * 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
CH517705A (en) * 1969-12-16 1972-01-15 Ciba Geigy Ag Process for the production of cystine-containing peptides
US3929758A (en) * 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US4033940A (en) * 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4093610A (en) * 1977-01-31 1978-06-06 American Home Products Corporation Process for producing triglycyl-lysine vasopressin and intermediates therefor
US4216141A (en) * 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
DE2923787A1 (en) * 1979-06-12 1980-12-18 Max Planck Gesellschaft METHOD FOR SELECTIVELY FORMING DISULFID BRIDGES IN POLYPEPTIDES AND THE PRODUCTS OBTAINED THEREOF AS MEDICINAL PRODUCTS
IE56021B1 (en) * 1982-10-13 1991-03-27 Akzo Nv Peptides
JPS61194034A (en) * 1985-02-25 1986-08-28 Teijin Ltd Powdery composition for transnasal administration
EP0300036A4 (en) * 1987-01-30 1989-06-14 Biomed Res Consultants Ltd Vasopressin-based pharmaceutical compositions.
US5066716A (en) * 1988-12-13 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
ATE108326T1 (en) * 1989-01-30 1994-07-15 Corint Ltd AQUEOUS MEDICATION CONTAINING DESMOPRESSIN-CMC.
DE69001991T2 (en) * 1989-11-16 1993-09-23 Phidea Spa LIQUID MEDICINAL APPLICATIONS CONTAINING A POLYPEPTIDE AS AN ACTIVE SUBSTANCE.

Also Published As

Publication number Publication date
NZ268442A (en) 1996-09-25
WO1995001183A1 (en) 1995-01-12
ATE203412T1 (en) 2001-08-15
CZ339095A3 (en) 1996-09-11
RU2135204C1 (en) 1999-08-27
HU9503833D0 (en) 1996-02-28
EP0708657B1 (en) 2001-07-25
US5498598A (en) 1996-03-12
PL176317B1 (en) 1999-05-31
SK165095A3 (en) 1996-11-06
HK1000906A1 (en) 2002-03-08
HU221617B1 (en) 2002-12-28
CN1126439A (en) 1996-07-10
CA2166312C (en) 2002-04-23
GR3036936T3 (en) 2002-01-31
DK0708657T3 (en) 2001-10-15
CN1101701C (en) 2003-02-19
KR960703339A (en) 1996-08-17
DE69427820D1 (en) 2001-08-30
ES2158898T3 (en) 2001-09-16
PT708657E (en) 2001-11-30
SK282844B6 (en) 2002-12-03
HUT73776A (en) 1996-09-30
EP0708657A1 (en) 1996-05-01
DE69427820T2 (en) 2001-11-08
CZ282456B6 (en) 1997-07-16
JPH09502425A (en) 1997-03-11
PL312204A1 (en) 1996-04-01
KR100193104B1 (en) 1999-06-15

Similar Documents

Publication Publication Date Title
CA2166312A1 (en) Compositions for nasal administration of desmopressin
PL316689A1 (en) Anti-dandruff shampoo
CA2308513A1 (en) Method and composition for delivering zinc to the nasal membrane
HK1000903A1 (en) Stabilized pharmaceutical peptide compositions
CA2203033A1 (en) Compounds and compositions for delivering active agents
HUT64567A (en) Method for producing new cyclosporines and preparations containing said compounds as active agent
AU3183389A (en) Human relaxin formulation
CA2345675A1 (en) Two chamber cartridge for atomizers
CA2277824A1 (en) Dosage composition for nasal delivery and method of use of the same
HUT75089A (en) Compositions containing hyaluronic acid or it's derivatives and pharmaceutical active agent
CA2342211A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
MY122262A (en) Lh-rh peptide analogues their uses and pharmaceutical compositions containing them
BG103930A (en) Eletriptan hemisulphate and caffeine containing pharmaceutical compositions
CA2311530A1 (en) Nasal solutions
MX9701170A (en) Low propellant aerosol antiperspirant composition.
CA2135614A1 (en) Use of urodilatin in pulmonary and bronchial diseases
AU2670495A (en) Ifn-beta liquid formulations
CA2033719A1 (en) Humectants in joint compound containers
BG103306A (en) Liquid allendronate compositions
NZ337798A (en) Pharmaceutical compositions containing lamivudine
CA2129921A1 (en) Stable aqueous solutions of hybrid .alpha.-interferon bdbb
YU40398A (en) A composition of nasal spray for administering a remedy for curing a delayed emesis fit
HU9402648D0 (en) 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens
IE840977L (en) Pharmaceutical preparations
CA2103667A1 (en) Liquid compositions based on 1,4 substituted piperidine derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed